Galectin Therapeutics Inc.
http://www.galectintherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Galectin Therapeutics Inc.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline
Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Gedeon Richter Investment In Formycon Opens Up Collaboration Opportunities
Gedeon Richter has agreed to acquire a stake of just over 9% in Formycon. The deal “opens up the possibility of jointly leveraging long-term strategic opportunities” while providing Formycon with more than €80m to invest in its biosimilar development projects.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- Galectin Sciences, LLC
- Pro-Pharmaceuticals Inc.
- Galectin Therapeutics Security Corp.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice